Detalles de la búsqueda
1.
Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
BMC Cancer
; 23(1): 547, 2023 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37322411
2.
Overall survival of patients with hepatocellular carcinoma treated with sintilimab and disease outcome after treatment discontinuation.
BMC Cancer
; 23(1): 1017, 2023 Oct 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-37867191
3.
Gemcitabine and cisplatin or oxaliplatin chemotherapy combined with atezolizumab plus bevacizumab for advanced biliary tract cancers: a single-arm trial.
Future Oncol
; 19(15): 1029-1035, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-37132469
4.
Hazard rate for postoperative recurrence in patients with hepatocellular carcinoma at Barcelona Clinic Liver Cancer stage 0 or A1: A multicenter observational study.
Hepatol Res
; 52(11): 947-956, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35839151
5.
Transarterial chemoembolization plus a PD-1 inhibitor with or without lenvatinib for intermediate-stage hepatocellular carcinoma.
Hepatol Res
; 52(8): 721-729, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35536197
6.
Transcatheter arterial chemoembolization plus atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: a single-arm, phase II trial.
Future Oncol
; 18(30): 3367-3375, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35968836
7.
Recurrence hazard rate in patients with hepatocellular carcinoma and bile duct tumor thrombus: a multicenter observational study.
HPB (Oxford)
; 24(10): 1703-1710, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35523655
8.
Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab versus Transarterial Chemoembolization Alone in Intermediate-stage Hepatocellular Carcinoma: A Multicenter Retrospective Study.
J Hepatocell Carcinoma
; 11: 1079-1093, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38882440
9.
Discovery of distinct cancer cachexia phenotypes using an unsupervised machine-learning algorithm.
Nutrition
; 119: 112317, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38154396
10.
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial.
Nat Med
; 30(3): 708-715, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38242982
11.
XAF1 promotes colorectal cancer metastasis via VCP-RNF114-JUP axis.
J Cell Biol
; 223(2)2024 02 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38095639
12.
Transarterial chemoembolization plus immune checkpoint inhibitor as postoperative adjuvant therapy for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter cohort study.
Eur J Surg Oncol
; 49(7): 1226-1233, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36739252
13.
Camrelizumab plus gemcitabine and oxaliplatin for the treatment of advanced intrahepatic cholangiocarcinoma: a bi-centric observational retrospective study.
Front Oncol
; 13: 1101038, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37197414
14.
Preoperative and Prognostic Prediction of Microvascular Invasion in Hepatocellular Carcinoma: A Review Based on Artificial Intelligence.
Technol Cancer Res Treat
; 22: 15330338231212726, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37933176
15.
Early Experience of TACE Combined with Atezolizumab plus Bevacizumab for Patients with Intermediate-Stage Hepatocellular Carcinoma beyond Up-to-Seven Criteria: A Multicenter, Single-Arm Study.
J Oncol
; 2023: 6353047, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37095751
16.
A reasonable identification of the early recurrence time based on microvascular invasion for hepatocellular carcinoma after R0 resection: A multicenter retrospective study.
Cancer Med
; 12(9): 10294-10302, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36880150
17.
Efficacy and safety of TACE combined with lenvatinib and PD-1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study.
Cancer Med
; 12(10): 11513-11524, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36999793
18.
Laparoscopic and open liver resection for hepatocellular carcinoma with type 2 diabetes mellitus: multicenter propensity score-matched study.
Hepatol Int
; 17(5): 1251-1264, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37060489
19.
Efficacy and safety of a triple combination of atezolizumab, bevacizumab plus GEMOX for advanced biliary tract cancer: a multicenter, single-arm, retrospective study.
Therap Adv Gastroenterol
; 16: 17562848231160630, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37007215
20.
Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: A preliminary multicenter single-arm prospective study.
Front Immunol
; 14: 1107542, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36875125